Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Net Income (2020 - 2025)

Tango Therapeutics has reported Net Income over the past 6 years, most recently at -$38.7 million for Q4 2025.

  • Quarterly results put Net Income at -$38.7 million for Q4 2025, down 2.86% from a year ago — trailing twelve months through Dec 2025 was -$101.6 million (up 22.03% YoY), and the annual figure for FY2025 was -$101.6 million, up 22.03%.
  • Net Income for Q4 2025 was -$38.7 million at Tango Therapeutics, down from $15.9 million in the prior quarter.
  • Over the last five years, Net Income for TNGX hit a ceiling of $15.9 million in Q3 2025 and a floor of -$39.9 million in Q1 2025.
  • Median Net Income over the past 5 years was -$26.8 million (2023), compared with a mean of -$25.0 million.
  • Biggest five-year swings in Net Income: tumbled 951806.78% in 2021 and later surged 154.46% in 2025.
  • Tango Therapeutics' Net Income stood at -$22.1 million in 2021, then tumbled by 31.77% to -$29.1 million in 2022, then fell by 5.82% to -$30.8 million in 2023, then fell by 22.5% to -$37.7 million in 2024, then decreased by 2.86% to -$38.7 million in 2025.
  • The last three reported values for Net Income were -$38.7 million (Q4 2025), $15.9 million (Q3 2025), and -$38.9 million (Q2 2025) per Business Quant data.